RAS MAPK Therapies And Expanding Trials Will Transform This Rare Cancer Specialist

Catalysts

About Verastem

Verastem Oncology focuses on developing and commercializing targeted therapies for RAS/MAPK pathway driven cancers.

What are the underlying business or industry changes driving this perspective?

• The commercial introduction of AVMAPKI FAKZYNJA CO-PACK as the first treatment specifically approved for KRAS mutated recurrent low grade serous ovarian cancer gives Verastem a defined niche in a rare disease setting. This can support more durable revenue per patient as physicians gain experience with prescribing and refills.
• Growing engagement with top academic centers, community oncologists and group purchasing organizations, including high activity across the top 100 organizations and offices, expands the prescriber base and can support broader product availability that feeds into net product revenue.
• Broad payer coverage with covered lives above 80%, fast time to fill of roughly 12 to 14 days and limited reimbursement barriers lowers friction for new prescriptions. This can support prescription volume, revenue visibility and working capital efficiency.
• The advancement of VS 7375, including cleared monotherapy doses, selection of a Phase II dose already used by a partner in China and the move into combination cohorts with cetuximab, positions Verastem to participate in growing interest in targeted KRAS G12D therapies. This could expand the revenue base and help absorb fixed operating costs over time.
• Completion of enrollment in key trials such as the confirmatory Phase III RAMP 301 in recurrent LGSOC and the first line pancreatic cancer trial RAMP 205, together with planned FDA interactions, concentrates future clinical readouts in large solid tumor indications. This can affect the company’s potential addressable market, future revenue scale and the ability to leverage current SG&A and R&D spending into earnings power.

Assumptions

This narrative explores a more optimistic perspective on Verastem compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Verastem's revenue will grow by 228.0% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -1802.1% today to 38.3% in 3 years time.
• The bullish analysts expect earnings to reach $180.8 million (and earnings per share of $2.03) by about January 2029, up from $-241.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-166.2 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 11.2x on those 2029 earnings, up from -2.3x today. This future PE is lower than the current PE for the US Biotechs industry at 21.1x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Verastem is still loss making, with a non GAAP adjusted net loss of $39.4 million in the third quarter of 2025 and R&D plus SG&A expenses of $50.0 million against $11.2 million of net product revenue. If AVMAPKI FAKZYNJA CO PACK prescription growth or refill rates fall short of expectations over time, the gap between revenue and operating costs could remain wide and delay a move toward positive earnings.
• The company expects its current cash of $137.7 million, together with future AVMAPKI FAKZYNJA CO PACK revenue and potential warrant exercises, to fund operations only into the second half of 2026. Slower than expected revenue build or higher than expected trial and commercial spending could increase financing needs and lead to dilution, affecting earnings per share and shareholder returns.
• The bullish view depends heavily on expanding use of AVMAPKI FAKZYNJA CO PACK and on favorable outcomes in trials like the RAMP 301 confirmatory study and RAMP 205. The independent data monitoring committee has already recommended an increase in RAMP 301 enrollment because there were not enough events to draw conclusions, so any future efficacy or safety outcomes that are less compelling than hoped could limit label expansion, reduce the long term revenue opportunity and weigh on margins.
• VS 7375 is described as having best in class potential among KRAS G12D inhibitors, but the program is still in early Phase I/IIa testing and the company plans to rely in part on harmonizing data from a partner in China. The broader RAS/MAPK field is highly competitive, so any unfavorable data, regulatory friction or better competing therapies could restrict future uptake and leave Verastem more dependent on a single commercial product, which would constrain revenue diversification and earnings growth.
• The company operates in a rare disease setting with a focused prescriber base, and management highlights that around 65% of AVMAPKI FAKZYNJA CO PACK prescriptions are currently concentrated in the top 100 organizations and that usage already includes some off label and KRAS wild type patients. If guideline decisions, payer policies or future data limit use to a narrower patient pool than physicians currently expect, long term prescription volumes and pricing power could be pressured, affecting both net product revenue and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Verastem is $20.0, which represents up to two standard deviations above the consensus price target of $16.0. This valuation is based on what can be assumed as the expectations of Verastem's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $472.1 million, earnings will come to $180.8 million, and it would be trading on a PE ratio of 11.2x, assuming you use a discount rate of 7.3%.
  
• Given the current share price of $7.23, the analyst price target of $20.0 is 63.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.